Modern Biosciences is a drug development company that in-licenses late-stage discovery projects from academia and spin out companies. Our team of experts plan and execute a focused development program for the in-licensed asset which typically includes proof-of-mechanism and/or proof-of-principle human studies. The resulting data package is intended to maximise the value of the asset prior to entering licensing negotiations with pharmaceutical or biotech partners.

Modern Biosciences’ three main business activities are in-licensing, project development and commercialisation.

Modern Biosciences’ office is based in the City of London and its founding investor is IP Group plc, a London Stock Exchange listed company.